6-phenoxy-3,4-dihydronaphthalen-1(2H)-one | 90401-82-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-phenoxy-3,4-dihydronaphthalen-1(2H)-one
• 英文别名: 6-phenoxy-3,4-dihydro-2H-naphthalen-1-one
• CAS: 90401-82-4
• 化学式: C₁₆H₁₄O₂
• 分子量: 238.286
• InChiKey: LTGNADIFWVNHCL-UHFFFAOYSA-N

物化性质

• 沸点：
  387.8±31.0 °C(Predicted)
• 密度：
  1.171±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-phenoxy-3,4-dihydronaphthalen-1(2H)-one 在 偶氮二甲酸二异丙酯 、 dimethyl sulfide borane 、 三苯基膦 、 sodium t-butanolate 作用下， 以 四氢呋喃 为溶剂， 反应 8.5h， 生成 2-[(6-Phenoxy-1,2,3,4-tetrahydronaphthalen-1-yl)methyl]isoindole-1,3-dione
  参考文献：
  名称：

  [EN] IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS
  [FR] DÉRIVÉS D'IMIDAZO[1,2-A]PYRIDINE UTILISÉS EN TANT QU'INHIBITEURS D'HISTONE DÉMÉTHYLASE

  摘要：

  这份披露涉及抑制组蛋白去甲基化酶活性的化合物等内容。具体而言，该披露涉及抑制组蛋白赖氨酸去甲基化酶KDM5B的化合物，药物组合物和使用方法，例如使用本文披露的化合物和药物组合物治疗癌症的方法。

  公开号：

  WO2017214413A1
• 作为产物：
  描述：

  6-甲氧基-1-萘满酮 在 氢溴酸 、 potassium hydrogencarbonate 、 copper(l) chloride 作用下， 生成 6-phenoxy-3,4-dihydronaphthalen-1(2H)-one
  参考文献：
  名称：

  Tetrahydronaphthalene-derived amino alcohols and amino ketones as potent and selective inhibitors of the delayed rectifier potassium current IKs

  摘要：

  Class III anti-arrhythmic drugs (e.g., dofetilide) prolong cardiac action potential duration (APD) by blocking the fast component of the delayed rectifier potassium current (I-Kr). The block of I-Kr can result in life threatening ventricular arrhythmias (i.e., torsades de pointes). Unlike I-Kr, the role of the slow component of the delayed rectifier potassium current (I-Ks) becomes significant only at faster heart rate. Therefore selective blockers Of I-Ks could prolong APD with a reduced propensity to cause proarrhythmic side effects. This report describes structure-activity relationships (SARs) of a series of I-Ks inhibitors derived from 6-alkoxytetralones with good in vitro activity (IC50 > 30 nM) and up to 40-fold I-Ks/I-Kr selectivity. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.10.003

文献信息

• [EN] HISTONE DEMETHYLASE INHIBITORS<br/>[FR] INHIBITEURS D'HISTONES DÉMÉTHYLASES
  申请人：CHRYSALIS INC

  公开号：WO2017143011A1

  公开（公告）日：2017-08-24

  This disclosure relates to compounds that inhibit histone demethylase activity. In particular, the disclosure relates to compounds that inhibit histone lysine demethylase KDM5B, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions disclosed herein.

  这份披露涉及抑制组蛋白去甲基化酶活性的化合物。具体而言，该披露涉及抑制组蛋白赖氨酸去甲基化酶KDM5B的化合物，以及使用这些化合物和药物组合物的方法，例如使用本文披露的化合物和药物组合物治疗癌症的方法。
• [EN] ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] ISOXAZOLINES EN TANT QU'INHIBITEURS DE L'HYDROLASE DES AMIDES D'ACIDES GRAS
  申请人：INFINITY PHARMACEUTICALS INC

  公开号：WO2010135360A1

  公开（公告）日：2010-11-25

  The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient. The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.

  本发明提供了式(I)的异噁唑啉FAAH抑制剂或其药用可接受形式，其中G、Ra、Rb、Rc和Rd中的每一个如本文所定义。本发明还提供了包括式(I)化合物或其药用可接受形式以及药用可接受赋形剂的药物组合物。本发明还提供了治疗FAAH介导疾病的方法，包括向需要的受试者施用式(I)化合物或其药用可接受形式的治疗有效量。
• [EN] HISTONE DEMETHYLASE INHIBITORS<br/>[FR] INHIBITEURS D'HISTONE DÉMÉTHYLASE
  申请人：QUANTICEL PHARMACEUTICALS INC

  公开号：WO2014100818A1

  公开（公告）日：2014-06-26

  The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本发明一般涉及治疗癌症和肿瘤性疾病的组合物和方法。本文提供了取代的吡啶或吡啶二氮杂环衍生物化合物和包含该化合物的药物组合物。所述化合物和组合物可用于抑制组蛋白去甲基化酶。此外，所述化合物和组合物可用于治疗癌症，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等。
• Synthesis and .BETA.-adrenergic blocking activity of 2-(N-substituted amino)-1,2,3,4-tetrahydronaphthalen-1-ol derivatives.
  作者：KATSUMI ITOH、AKIO MIYAKE、NORIO TADA、MINORU HIRATA、YOSHIKAZU OKA

  DOI：10.1248/cpb.32.130

  日期：——

  In a search for a new structural type of β-adrenergic antagonist. a series of trans-2-(N-substituted amino)-1, 2, 3, 4-tetrahydronaphthalen-1-ol derivatives (3-36) was synthesized in several steps from 3, 4-dihydro-1 (2H)-naphthalenone (37) having a variety of substituents at the 5-, 6-, 7-and 8-positions. Compounds 3-36 were tested in vitro for β-adrenergic activity. Among them, 2-benzhydrylamino-6-chloro-1, 2, 3, 4-tetrahydronaphthalen-1-ol (28c) was found to show a fairly potent β-adrenergic blocking activity.

  为了寻找一种新结构类型的 β-肾上腺素能拮抗剂，我们从 5、6、7 和 8 位上具有各种取代基的 3、4-二氢-1(2H)-萘酮（37）出发，通过几个步骤合成了一系列反式-2-（N-取代氨基）-1，2，3，4-四氢萘-1-醇衍生物（3-36）。体外测试了 3-36 号化合物的 β 肾上腺素能活性。其中，2-二苯甲基氨基-6-氯-1，2，3，4-四氢萘-1-醇（28c）显示出相当强的β-肾上腺素能阻断活性。
• HISTONE DEMETHYLASE INHIBITORS
  申请人：Quanticel Pharmaceuticals, Inc.

  公开号：US20150119397A1

  公开（公告）日：2015-04-30

  The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本发明涉及治疗癌症和肿瘤疾病的组合物和方法。本发明提供了取代的酰胺吡啶或酰胺吡嗪衍生物化合物和含有该化合物的制药组合物。所述化合物和组合物可用于抑制组蛋白去甲基化酶。此外，所述化合物和组合物可用于治疗癌症，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等。